Kimball Electronics (KE) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Fiscal 2024 began with record sales and strong Q1, but macro headwinds led to cost reductions, team resizing, and strategic focus on core EMS operations.
76% of revenue came from long-term customers, and the company received multiple service excellence awards.
Published the 2023 Guiding Principles Report, highlighting ESG achievements and sustainability as a core value.
Annual meeting scheduled for November 15, 2024, with four key proposals for shareholder vote.
Voting matters and shareholder proposals
Election of two directors for three-year terms: Gregory J. Lampert and Colleen C. Repplier.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal 2025.
Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes (Board recommends annual vote).
Board of directors and corporate governance
Board is classified into three tiers, with staggered three-year terms for stability and long-term focus.
Majority independent board, with separate Chairperson and CEO roles; strong independent committee chairs.
Board diversity: 3 of 8 directors are women; 52% of global workforce is female; ongoing commitment to diversity, equity, and inclusion.
Board committees: Audit, Nominating and ESG, and Talent, Culture, and Compensation, all composed of independent directors.
Directors receive a mix of cash and equity compensation, with options to defer or receive in stock.
Latest events from Kimball Electronics
- Raised FY26 guidance and expanded medical focus drive profitable growth outlook.KE
Company presentation20 Mar 2026 - Medical segment growth and facility expansion drive strategic shift and margin improvement.KE
2026 KeyBanc Capital Markets Healthcare Forum19 Mar 2026 - Q2 sales fell 5% but margins and 2026 guidance improved on strong medical growth.KE
Q2 20265 Feb 2026 - Q4 sales dropped 13% as inventory and liquidity improved; 2025 outlook remains cautious.KE
Q4 20241 Feb 2026 - Streamlined operations and global focus drive resilience despite EMS market headwinds.KE
The Stifel 2024 Cross Sector Insight Conference31 Jan 2026 - FY 2025 sales expected to decline 8–14% as focus shifts to automation, medical, and debt reduction.KE
2024 Annual Gateway Conference22 Jan 2026 - Q1 sales fell 15% as restructuring, divestitures, and strong cash flow drove debt reduction.KE
Q1 202516 Jan 2026 - Strategic medical CMO expansion and operational discipline set the stage for future growth.KE
The Gateway Conference 20255 Jan 2026 - Q2 FY25 net sales fell 15% year-over-year, but liquidity and balance sheet improved.KE
Q2 202523 Dec 2025